Neurocrine Biosciences, Inc. (NBIX), Friday announced the commercial launch of Crenessity in the U.S. for adult and pediatric patients with classic congenital adrenal hyperplasia or CAH, a rare genetic condition.
The announcement follows the U.S. Food and Drug Administration's approval of Crenessity as an adjunctive treatment to glucocorticoid replacement to control androgens in CAH patients.
The biopharmaceutical company added that the medication will be exclusively available through PANTHERx Rare, a specialty pharmacy.
During the pre-market hours, Neurocrine's stock is trading at $134.01, down 0.70 percent on the Nasdaq.
For comments and feedback contact: editorial@rttnews.com
Health News
June 19, 2026 16:46 ET Major central banks continued to dominate the economic news flow this week too, led by the Federal Reserve, as they announced their latest policy decisions. The Federal Reserve policy session was in focus as it was the first to be led by the new chief Kevin Warsh. In Europe, central banks of the U.K. and Switzerland announced their rate decisions. In Asia, the Bank of Japan drew attention for its policy moves, while data out of China threw some light on the state of the economy.